Market closedNon-fractionalADR
Avadel Pharmaceuticals/AVDL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Avadel Pharmaceuticals
Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's lead product, LUMRYZ, is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME and MEDUSA. Its MICROPUMP technology allows for the development of modified release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
Ticker
AVDL
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
Headquarters
Dublin, Ireland
Employees
154
Website
www.avadel.com
AVDL Metrics
BasicAdvanced
$1.5B
Market cap
-
P/E ratio
-$1.86
EPS
1.74
Beta
-
Dividend rate
Price and volume
Market cap
$1.5B
Beta
1.74
52-week high
$19.09
52-week low
$9.50
Average daily volume
24
Financial strength
Current ratio
2.845
Quick ratio
2.596
Interest coverage (TTM)
-14.71%
Management effectiveness
Return on assets (TTM)
-101.63%
Return on equity (TTM)
-780.02%
Return on investment (TTM)
-172.85%
Valuation
Price to revenue (TTM)
27.803
Price to book
19.554
Price to tangible book (TTM)
24.909
Growth
Earnings per share change (TTM)
20.30%
3-year revenue growth (CAGR)
7.78%
What the Analysts think about AVDL
Analyst Ratings
Majority rating from 10 analysts.
AVDL Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$27M
39.69%
Net income
-$27M
-4.88%
Profit margin
-100.73%
-31.91%
AVDL Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.83
-$0.41
-$0.29
-$0.30
-
Expected
-$0.38
-$0.37
-$0.26
-$0.21
-$0.16
Surprise
115.98%
10.14%
11.83%
44.38%
-
AVDL News
AllArticlesVideos
Avadel Pharmaceuticals to Join Russell 3000® Index
GlobeNewsWire·4 weeks ago
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
GlobeNewsWire·2 months ago
Avadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractionalADR
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Avadel Pharmaceuticals stock?
Avadel Pharmaceuticals (AVDL) has a market cap of $1.5B as of July 27, 2024.
What is the P/E ratio for Avadel Pharmaceuticals stock?
The price to earnings (P/E) ratio for Avadel Pharmaceuticals (AVDL) stock is 0 as of July 27, 2024.
Does Avadel Pharmaceuticals stock pay dividends?
No, Avadel Pharmaceuticals (AVDL) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Avadel Pharmaceuticals dividend payment date?
Avadel Pharmaceuticals (AVDL) stock does not pay dividends to its shareholders.
What is the beta indicator for Avadel Pharmaceuticals?
Avadel Pharmaceuticals (AVDL) has a beta rating of 1.74. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Avadel Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.